BR0012002A - Composição para interagir com um ligando, uso de um conjugado compreendendo um grupo dianteiro e um grupo traseiro, método para produzir uma composição para interagir com um ligando, e, método para produzir uma molécula para interagir com um ligando - Google Patents

Composição para interagir com um ligando, uso de um conjugado compreendendo um grupo dianteiro e um grupo traseiro, método para produzir uma composição para interagir com um ligando, e, método para produzir uma molécula para interagir com um ligando

Info

Publication number
BR0012002A
BR0012002A BR0012002-2A BR0012002A BR0012002A BR 0012002 A BR0012002 A BR 0012002A BR 0012002 A BR0012002 A BR 0012002A BR 0012002 A BR0012002 A BR 0012002A
Authority
BR
Brazil
Prior art keywords
ligand
interacting
composition
producing
group
Prior art date
Application number
BR0012002-2A
Other languages
English (en)
Inventor
Roger New
Istvan Toth
Original Assignee
Proxima Concepts Ltd
Mozaico Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proxima Concepts Ltd, Mozaico Discovery Ltd filed Critical Proxima Concepts Ltd
Publication of BR0012002A publication Critical patent/BR0012002A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

"COMPOSIçãO PARA INTERAGIR COM UM LIGANDO, USO DE UM CONJUGADO COMPREENDENDO UM GRUPO DIANTEIRO E UM GRUPO TRASEIRO, MéTODO PARA PRODUZIR UMA COMPOSIçãO PARA INTERAGIR COM UM LIGANDO, E, MéTODO PARA PRODUZIR UMA MOLéCULA PARA INTERAGIR COM UM LIGANDO". Uma composição para interagir com um ligando, a qual compreende uma associação não-covalente de uma pluralidade de conjugados distintos, cada conjugado compreendendo um grupo dianteiro e um grupo traseiro, sendo que os grupos traseiros dos conjugados formam uma agregação hidrofóbica e os conjugados são móveis dentro da associação de modo que, na presença de um ligando, pelo menos dois dos grupos dianteiros são apropriadamente posicionados para formar um epitopo capaz de interagir com o ligando mais fortemente do que cada um dos grupos dianteiros individualmente.
BR0012002-2A 1999-06-28 2000-06-27 Composição para interagir com um ligando, uso de um conjugado compreendendo um grupo dianteiro e um grupo traseiro, método para produzir uma composição para interagir com um ligando, e, método para produzir uma molécula para interagir com um ligando BR0012002A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915074.0A GB9915074D0 (en) 1999-06-28 1999-06-28 Ligand-binding composition
PCT/GB2000/002465 WO2001001140A1 (en) 1999-06-28 2000-06-27 Epitopes formed by non-covalent association of conjugates

Publications (1)

Publication Number Publication Date
BR0012002A true BR0012002A (pt) 2002-03-12

Family

ID=10856190

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012002-2A BR0012002A (pt) 1999-06-28 2000-06-27 Composição para interagir com um ligando, uso de um conjugado compreendendo um grupo dianteiro e um grupo traseiro, método para produzir uma composição para interagir com um ligando, e, método para produzir uma molécula para interagir com um ligando

Country Status (18)

Country Link
US (2) US7413538B1 (pt)
EP (2) EP1190255B1 (pt)
JP (1) JP4754136B2 (pt)
KR (1) KR100917285B1 (pt)
CN (1) CN100354628C (pt)
AT (2) ATE457460T1 (pt)
AU (1) AU775310B2 (pt)
BR (1) BR0012002A (pt)
CA (1) CA2377783C (pt)
DE (2) DE60043830D1 (pt)
DK (1) DK1190255T3 (pt)
ES (1) ES2292446T3 (pt)
GB (1) GB9915074D0 (pt)
HK (1) HK1045369A1 (pt)
IL (2) IL147249A0 (pt)
PT (1) PT1190255E (pt)
RU (1) RU2259194C2 (pt)
WO (1) WO2001001140A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1789797A1 (en) 2004-09-03 2007-05-30 Receptors LLC Combinatorial artifical receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
WO2008035093A2 (en) * 2006-09-20 2008-03-27 Lexcicon Limited Peptides
KR100840619B1 (ko) * 2006-12-19 2008-06-24 한양대학교 산학협력단 표면개질된 리포좀, 이를 포함하는 바이오칩 및 그제조방법
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
RU2500813C1 (ru) * 2012-10-15 2013-12-10 Федеральное казенное учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения липосомально-иммунопероксидазного конъюгата
KR101491728B1 (ko) * 2012-12-14 2015-02-11 주식회사 휴메딕스 비타민 c와 비타민 b3의 컨쥬게이트 및 그를 포함하는 항산화제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3813821A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
SG47406A1 (en) * 1991-12-19 1998-04-17 Ciba Geigy Ag Aminosulfonic acid derivatives and processes for their preparation
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
JP2579730B2 (ja) * 1993-01-22 1997-02-12 株式会社ディ・ディ・エス研究所 ペプチド−脂質誘導体及びリポソーム
CA2167282A1 (en) * 1993-07-16 1995-01-26 Gerald R. Crabtree Regulated apoptosis
JP3759759B2 (ja) * 1994-03-04 2006-03-29 日本油脂株式会社 リポソームおよび薬物運搬体
EP0706799B1 (en) * 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5851536A (en) * 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
WO1997049425A1 (en) * 1996-06-25 1997-12-31 Stichting Instituut Voor Dierhouderij En Diergezondheid Vaccine comprising antigens bound to carriers through labile bonds
JPH10234372A (ja) * 1997-02-27 1998-09-08 Boehringer Mannheim Corp キメラ受容体を有する細胞とその作成方法、並びに その利用
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
WO1999051629A2 (en) * 1998-04-07 1999-10-14 Roche Diagnostics Gmbh New compounds for dna-transfection
AU3191100A (en) * 1999-03-17 2000-10-04 Mitsubishi Chemical Corporation Ligand-bonded complex
WO2000061114A1 (fr) * 1999-04-08 2000-10-19 Mitsubishi Chemical Corporation Particules fines ciblant des cellules, et procede de production correspondant
JP4111368B2 (ja) * 1999-04-23 2008-07-02 三菱化学株式会社 抗体およびポリアルキレングリコール結合リポソーム
CA2369595C (en) * 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome

Also Published As

Publication number Publication date
HK1045369A1 (en) 2002-11-22
EP1722227A3 (en) 2007-02-28
PT1190255E (pt) 2007-09-18
AU775310B2 (en) 2004-07-29
EP1722227A2 (en) 2006-11-15
KR20020042537A (ko) 2002-06-05
CN1359469A (zh) 2002-07-17
IL147249A0 (en) 2002-08-14
EP1190255B1 (en) 2007-08-22
JP2003503424A (ja) 2003-01-28
AU5692300A (en) 2001-01-31
RU2259194C2 (ru) 2005-08-27
US20080152703A1 (en) 2008-06-26
CN100354628C (zh) 2007-12-12
GB9915074D0 (en) 1999-08-25
EP1190255A1 (en) 2002-03-27
DK1190255T3 (da) 2007-12-10
CA2377783C (en) 2010-03-23
ATE371190T1 (de) 2007-09-15
DE60036106T2 (de) 2008-05-15
DE60043830D1 (de) 2010-03-25
DE60036106D1 (de) 2007-10-04
US7413538B1 (en) 2008-08-19
CA2377783A1 (en) 2001-01-04
WO2001001140A1 (en) 2001-01-04
EP1722227B1 (en) 2010-02-10
IL147249A (en) 2007-08-19
ATE457460T1 (de) 2010-02-15
ES2292446T3 (es) 2008-03-16
JP4754136B2 (ja) 2011-08-24
KR100917285B1 (ko) 2009-09-11

Similar Documents

Publication Publication Date Title
BR0012002A (pt) Composição para interagir com um ligando, uso de um conjugado compreendendo um grupo dianteiro e um grupo traseiro, método para produzir uma composição para interagir com um ligando, e, método para produzir uma molécula para interagir com um ligando
ES2118662T3 (es) Articulacion para butaca de vehiculo y butaca de vehiculo equipada con dicha articulacion.
ATE144523T1 (de) Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
BR9006089A (pt) Guarnicao de articulacao para assentos com espaldar regulavel,sobretudo assentos de veiculo motorizado
PT983087E (pt) Composicao de vacina multivalente com veiculo misto
SG165158A1 (en) Calicheamicin derivative-carrier conjugates
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
BR0210828A (pt) Preparações de agentes corantes à base de água para a impressão inkjet
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
BR0013642A (pt) Análogos de nucleosìdeo de pirrolo[2,3-d]pirimidina
ZA200105538B (en) Compositions comprising flavylium salt compounds which are unsubstituted in Position 3, for colouring the skin, and uses thereof.
WO2002096367A3 (en) Targeted multivalent macromolecules
DE69708340D1 (de) Arylsulfonylimidazolon-derivate als antitumormittel
DE58903326D1 (de) Verstellschienenanordnung, insbesondere fuer pkw-sitze.
BR9710537B1 (pt) derivados da eritromicina, composições farmacêuticas, bem como processo para preparação dos mesmos.
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
AR023979A1 (es) Procesos para preparar compuestos intermedios de plaguicidas
KR880010721A (ko) 침대 겸용 쇼파
BR9906821A (pt) Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
HUT61561A (en) Process for producing octadecyl-/2-(n-methylpiperidino)-ethyl/-phosphate and pharmaceutical compositions comprising same as active ingredient
ES2023496B3 (es) Asiento regulable y abatible, en especial para vehiculo.
AU2620100A (en) Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
IT7819066A0 (it) Procedimento per produrre dispersioni acquose, stabili nella viscosita', per masse spalmabili su carta.
ES2035334T3 (es) Maquina para brochar.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MOZAICO DISCOVERY LIMITED (GB)

Free format text: TRANSFERIDO DE: PROXIMA CONCEPTS LIMITED

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements